TX-CIRRUS-LOGIC
Cirrus Logic (Nasdaq: CRUS) today unveiled the latest devices in its Pro Audio product family: a series of digital-to-analog converters (DACs) and an ultra-high performance audio CODEC that set a new standard for the prosumer and professional audio markets. These new solutions cater to the needs of recording artists, live performers, and audiophiles, delivering transparent audio converters to ensure recording and playback without any compromise in sound quality.
This launch expands on last year's successful analog-to-digital converters (ADCs) launch. Crafted with a focus on superior analog functionality and digital integration, these devices from Cirrus Logic offer exceptional performance, minimal power requirements, and innovative features like hybrid gain control, addressing longstanding audio challenges in the industry.
“True transparency in audio—that’s the hallmark of Cirrus Logic’s Pro Audio Family. It’s not just about sound, it’s about the authenticity from creation to consumption. Our commitment is purity in audio reproduction, ensuring that what you hear is as true to the original as possible,” said Eddie Sinnott, Director of Product Marketing. “With this new series of flagship audio products, we’re setting a gold standard for both professionals and prosumers, enabling our customers to create distinctive products with the confidence of our world-class engineering and support.”
Cirrus Logic CS4308P/CS4304P/CS4302P DACs and CS4282P CODEC
Designed with ease of use in mind, the Cirrus Logic Pro Audio 8-channel DAC CS4308P, 4-channel CS4304P, 2-channel CS4302P and CODEC CS4282P seamlessly integrate within a wide range of audio equipment. These new devices offer configurable advanced digital filters allowing our customers to define their signature sound. Cirrus Logic designs the devices with users in mind, making them as simple as possible to integrate and extract their full potential.
“As a long-time user of Cirrus Logic, we are excited about the new additions to its family of DAC and CODEC products being launched today,” said Simon Jones, CTO, Focusrite Group. “Cirrus Logic’s desire to keep setting the benchmark in audio quality is evident. These devices are designed to flawlessly integrate with a diverse spectrum of audio equipment, from USB audio interfaces to professional speakers and musical instruments. The addition of a hybrid gain control system into the CODEC and new ADC’s is a game changer for system integration that we really appreciate. At Focusrite, crafting audio interfaces is not just our business; it’s our passion. We bridge the gap between the artist and the audience, ensuring the sound conveyed is pristine.”
Exceptional Efficiency with Leading-Edge performance
The Pro Audio family also offers industry-leading power efficiency at 10 mW/ch for the 8/4-channel DACs, underlining Cirrus Logic’s longstanding commitment to bringing energy-efficient products to market. These new devices are 32-bit offering sample rates of up to 768 kHz, providing 129 dB of dynamic range for the CS4302P/CS4282P and 123 dB for the CS4304/8P. THD+N for these devices are all -114 dB or lower.
Product Availability
Samples of the CS4304/8P DACs and the CS4282P are available to order now. The converters are controllable and configurable using Cirrus Logic’s SoundClear® Studio software, which is available at www.cirrus.com. Samples of the CS4302P DAC will follow, later in the year.
Cirrus Logic Inc.
Cirrus Logic is a leader in low-power, high-precision mixed-signal processing solutions that create innovative user experiences for the world’s top mobile and consumer applications. With headquarters in Austin, Texas, Cirrus Logic is recognized globally for its award-winning corporate culture. Check us out at www.cirrus.com.
Cirrus Logic, Cirrus and the Cirrus Logic logo are registered trademarks of Cirrus Logic, Inc. All other company or product names noted herein may be trademarks of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625199957/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
